Seres Therapeutics Reports Narrowed Losses, Eyes Strategic Partnerships for Pipeline Advancement
Event summary
- Seres Therapeutics reported a net income of $5.7 million for 2025, a significant improvement from a $125.8 million loss in 2024, driven by lower operating expenses and gains from the VOWST sale.
- The company expects to report clinical data from an investigator-sponsored study of SER-155 for immune checkpoint-related enterocolitis in Q2 2026.
- Seres has $45.8 million in cash as of December 31, 2025, with a runway extending into Q3 2026.
- The company is seeking partnerships to advance its SER-155 program for allogeneic hematopoietic stem cell transplant (allo-HSCT) and SER-603 for inflammatory bowel disease (IBD).
The big picture
Seres Therapeutics is focusing on its inflammatory and immune disease pipeline, particularly SER-155 and SER-603, as it seeks to secure partnerships to support further development. The company's improved financial position in 2025, driven by cost management and gains from the VOWST sale, provides a stronger foundation for these efforts. The biotechnology sector continues to emphasize strategic collaborations to advance novel therapies, and Seres' ability to leverage its live biotherapeutic platform will be key to its success.
What we're watching
- Pipeline Progress
- The pace at which Seres can advance its SER-155 and SER-603 programs will determine its ability to attract strategic partners and secure additional funding.
- Financial Sustainability
- Whether Seres can extend its cash runway beyond Q3 2026 through partnerships or other funding sources will be critical for its long-term viability.
- Clinical Data Impact
- How the Q2 2026 clinical data readout for SER-155 in immune checkpoint-related enterocolitis will influence investor confidence and potential partnership discussions.
Related topics